Pfizer opens new $68.5M gene therapy facility

Dec. 16, 2021

Pfizer announced the opening of a new, state-of-the-art clinical manufacturing facility, growing its end-to-end capabilities in gene therapy and building on its existing footprint in North Carolina.

Pfizer, who has invested heavily in expanding its gene therapy capabilities, spent $68.5 million to build its new Durham, NC facility. The facility is part of an $800 million investment over the past six years to build three scalable gene therapy manufacturing facilities.

The Durham facility will be home to Pfizer’s BioTherapeutics Pharmaceutical Sciences Group, which is responsible for the manufacturing and analytical release of clinical supplies for Pfizer’s gene therapy and biologics portfolio. The drugmaker's current portfolio includes three late-stage clinical programs for hemophilia A, hemophilia B and Duchenne muscular dystrophy (DMD), as well as 12 preclinical programs investigating potential treatments for rare cardiology, endocrine, hematology, metabolic and neurology diseases.